Extended Data Fig. 4: Lipidomic profiles following 24-hour ELOVL6i treatment.
From: ELOVL6 activity attenuation induces mutant KRAS degradation
a, Untargeted lipidomic analysis of PS levels in NCI-H727 and HT29 cell lines after 24 h of treatment with 40 µM ELOVL6i from three biological replicates. Data are shown as molar fractions. b, KEGG pathway enrichment analysis of enriched lipids in ELOVL6i-treated NCI-H727 cells calculated using two-sided Fisher’s exact test. c, Molar fractions of asymmetrical PS species in NCI-H727 control and ELOVL6i treated cells (P = 0.044). d, Molar fractions of asymmetrical PS species in HT29 control and ELOVL6i treated cells. Statistical significance was determined by a two-tailed unpaired T-test. *P < 0.05, data are represented as mean ± s.d. FA: fatty acid.
